Analyzing Metabolites in Scleroderma and Related Conditions
Official title: Metabolomic Analysis of Systemic Sclerosis
Run by University Hospital, Strasbourg, France · NCT02298777 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is trying to find unique metabolic patterns in people with scleroderma and related conditions to help with early diagnosis and understanding the disease better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 5 sites (Dijon and 4 other locations) |
| Trial ID | NCT02298777 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with systemic sclerosis, undifferentiated connective tissue disease, primary Raynaud's disease, vascular disease, or healthy controls without any connective tissue disease.
✕Probably not a fit
Patients with other autoimmune diseases or those not meeting the specific diagnostic criteria for the included conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify distinct metabolic profiles associated with systemic sclerosis (SSc) and related conditions, focusing on early diagnosis and prognosis. By comparing metabolomic data from patients with early-stage SSc to those with established disease, as well as to individuals with undifferentiated connective tissue disease, Raynaud's disease, vascular disease, and healthy controls, the study seeks to uncover potential biomarkers. Participants will provide blood, urine, and skin samples for comprehensive analysis of their metabolomic profiles.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better management of systemic sclerosis and related conditions.
How similar studies have gone: While the approach of using metabolomic analysis is gaining traction, this specific study's focus on early-stage systemic sclerosis is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Group 1 (scleroderma) : Patients with ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001) * Group 2 (UCDT) : Patients with criteria proposed by Mosca et al. (1998) * Group 3 (Raynaud) : Patients with primary and isolated Raynaud disease * Group 4 (vascular disease) : Patients with type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke * Group 5 (healthy control) : healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease) Exclusion criteria: * Group 1 (scleroderma) : Patients not fulfilling ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001), or with another auto-immune disease * Group 2 (UCDT) : Patients not fulfilling criteria proposed by Mosca et al. (1998) * Group 3 (Raynaud) : Patients with no Raynaud disease * Group 4 (vascular disease) : Patients with no vascular disease * Group 5 (healthy control) : Patients with sign of connective tissue disease, Raynaud, or vascular disease)
Where it's running
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, France Recruiting -
Chu
Dijon, France Completed -
Hôpitaux privés de Metz
Metz, France Completed -
Chu
Nancy, France Withdrawn -
Chu
Reims, France Active not recruiting
Study contacts
- Principal investigator: Chatelus Emmanuel, MD — Hôpitaux Universitaires de Strasbourg
- Study coordinator: Chatelus Emmanuel, MD
- Email: emmanuel.chatelus@chru-strasbourg.fr
- Phone: 03 88 12 81 15
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pet imaging of sigma1 receptors in healthy adults
This study tests two sigma-1 radiotracers, to see how well they image the brain in healthy adults and how reliably the imaging measurements work.
-
Understanding how social thinking, brain signals, and iron biology change with age in schizophrenia
This study tests whether social cognition and brain biology change over time in people with schizophrenia compared to healthy adults.
-
Imaging PD progression with [18F]AV-133 using high- and standard-resolution PET
This study tests how [18F]AV-133 PET imaging changes over 12 months in people with Parkinson's disease and a small group of healthy controls.
-
Biopsychosocial (BETY) exercise program for children and adults with scleroderma
This project will test whether BETY, a biopsychosocial exercise program, helps children and adults with scleroderma improve physical function and psychosocial well-being.
-
Physical performance and daily function in people with scleroderma
This project will test which questionnaires and simple physical tests best measure physical performance and daily functioning in children and adults with scleroderma.
-
Chewing and swallowing performance in people with scleroderma
This project will see how children and adults with scleroderma chew and swallow and collect biopsychosocial information using questionnaires.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.